Search Menu Executive Committee Rob Kowalski Chief People & Organization Officer since September 1, 2021 Biography Summary As Chief People & Organization (P&O) Officer of Novartis, Rob Kowalski leads the company’s strategy to unleash the power of its more than 100,000 employees to support its long-term priorities and purpose. Rob took on his current role in 2021. He leads the P&O function at a time when the global pandemic continues to reshape the global working environment and Novartis is accelerating the adoption of new working models for employees to optimize both personal and business performance. I am a firm believer in the Novartis culture, which aims to inspire employees, stimulate their curiosity and promote an unbossed style of leadership. Through transforming our culture, we aim to provide more value for employees and generate a source of long-term competitive advantage, while ensuring we continue to innovate for patients. Rob is passionate about creating a diverse, inclusive and equitable environment where all employees can fully apply their talents and energies. He is responsible for delivering on the company’s pledge to the United Nations (UN) Equal Pay International Coalition to achieve gender balance in management and further improve pay equity and transparency processes by 2023. Rob has held a range of other senior leadership roles at Novartis, and is known for his skill in building and leading diverse organizations. In his previous role as Global Head of Regulatory Affairs, he led an organization that has delivered a dozen new molecular entity approvals in the three years through 2020. Rob holds a doctor of pharmacy degree from the University of Wisconsin-Madison, US. Disclaimer Information is accurate as of Sep 1, 2021 Novartis Navigate Topics Explore Companies © 2021 Novartis AG Terms of Use Privacy Contacts Cookie Settings Site Map Novartis Site Directory This site is intended for a global audience

Search Menu Share Data & Analysis Dividend Information Continuously rising dividend since 1996 Shareholders approved the 24th consecutive dividend increase per share since the creation of Novartis in 1996, with an increase of 1.7% to CHF 3.00 per share for 2020. The dividend payment date has been set for March 08, 2021. From March 04, 2021, the shares have been trading ex-dividend. Total dividend per share (CHF) Business year Dividend (CHF) 1997 0,63 1998 0,73 1999 0,80 2000 0,85 2001 0,90 2002 0,95 2003 1,00 2004 1,05 2005 1,15 2006 1,35 2007 1,60 2008 2,00 2009 2,10 2010 2,20 2011 2,25 2012 2,30 2013 2,45 2014 2,60 2015 2,70 2016 2,75 2017 2,80 2018 2,85 2019 2,95 2020 3,00 Find more information about the dividend in the Annual Report 2020 Visit our return on investment calculator Novartis Navigate Topics Explore Companies © 2021 Novartis AG Terms of Use Privacy Contacts Cookie Settings Site Map Novartis Site Directory This site is intended for a global audience